Publications by authors named "A L Pichard"
Background: Radiolabeled-antibodies usually display non-specific liver accumulation that may impair image analysis and antibody biodistribution. Here, we investigated whether Fc silencing influenced antibody biodistribution. We compared recombinant Zr-labeled antibodies (human IgG1 against different targets) with wild-type Fc and with mutated Fc (LALAPG triple mutation to prevent binding to Fc gamma receptors; FcγR).
View Article and Find Full Text PDFObjectives: To assess the current management of menopause in France with regard to menopause-related and genitourinary symptoms, with a focus on use of menopause hormone therapy (MHT).
Design, Setting, And Participants: The ELISA Study is a population-based survey of 5004 French representative women aged 50 to 65 years. From July to August 2020, the participating women answered an online computer-assisted web interview on menopause-related and genitourinary symptoms and their management, including use of MHT.
Article Synopsis
- Targeted radionuclide therapy (TRT) is an alternative approach for treating metastatic tumors, offering lower side effects compared to conventional external beam radiotherapy (EBRT) by delivering continuous low doses of radiation.
- The effectiveness of TRT and EBRT differs, with TRT needing adjustments to traditional models like the sigmoid curve to account for tissue repair times and additional biological factors such as bystander effects and immune response.
- Researchers suggest that the dose rate in TRT significantly influences the balance between direct DNA damage and broader biological responses involving cellular communication and the immune system.
Purpose: Non-targeted effects, including bystander and systemic effects, play a crucial role during Auger targeted radionuclide therapy. Here, we investigated whether small extracellular vesicles (sEVs) produced by irradiated cells could contribute to the bystander cytotoxic effects in vitro and also to therapeutic efficacy in vivo, after their injection in tumor xenografts.
Materials And Methods: B16F10 melanoma donor cells were exposed to radiolabeled antibodies (Auger radioimmunotherapy, RIT) for 48 h or to X-rays (donor cells).